European Companies Search Engine
EU funding (€10.2M): FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA Hor1 Jan 2020 EU Research and Innovation programme "Horizon"
Overview
Text
FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization. FAIR's objectives are to: • develop nebulization modalities for optimal airway targeting and rapid action at the infection site • demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibiotic-resistant pneumonia • identify host immune factors required for the gain of protection with systems biology • implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation • assess nebulized flagellin's safety in a Phase I clinical trial. • analyze the acceptability and economic relevance of the therapy • identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts. Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.
Funded Companies:
| Company name | Funding amount |
| Aerogen Ltd. | €196,625 |
| Centre Hospitalier Regional Universitaire de Tours | €543,206 |
| Commissariat a L Energie Atomique et aux Energies Alternatives | €0.00 |
| EPITHELIX Sàrl | €482,896 |
| European Lung Foundation | €0.00 |
| EUROPEAN RESPIRATORY SOCIETY | €132,375 |
| FREIE UNIVERSITAET BERLIN | €507,750 |
| Inserm Transfert SA | €247,875 |
| Institut National de la Sante et de la Recherche Medicale | €3,210,326 |
| Institut Pasteur de Lille Fondation | €0.00 |
| Statens Serum Institut | €3,141,529 |
| STICHTING AMSTERDAM UMC | €1,251,170 |
| Universite de Lille | €174,087 |
| Universite de Tours | €0.00 |
| University of Southampton | €275,064 |
Source: https://cordis.europa.eu/project/id/847786
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Aerogen Ltd. - EU funding (€10.2M): FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
